Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis

[1]  S. Teichmann,et al.  Developmental cell programs are co-opted in inflammatory skin disease , 2021, Science.

[2]  J. Krueger,et al.  Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. , 2020, The journal of allergy and clinical immunology. In practice.

[3]  Ning Zhang,et al.  Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. , 2020, The Journal of allergy and clinical immunology.

[4]  J. Lapointe,et al.  Immunohistochemical characterisation of the IL-13:IL-4Rα axis in the skin of moderate-severe adult atopic dermatitis patients and healthy controls. , 2020, The Journal of investigative dermatology.

[5]  G. Singer,et al.  Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis. , 2020, The Journal of allergy and clinical immunology.

[6]  T. Bieber.  Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis , 2020, Allergy.

[7]  J. North,et al.  Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis. , 2019, Journal of the American Academy of Dermatology.

[8]  S. Grässel,et al.  Housekeeping gene validation for RT-qPCR studies on synovial fibroblasts derived from healthy and osteoarthritic patients with focus on mechanical loading , 2019, PloS one.

[9]  Ruilian Li,et al.  Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trial , 2019, Journal of immunology research.

[10]  James T. Elder,et al.  Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. , 2019, The Journal of investigative dermatology.

[11]  M. Lebwohl,et al.  Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with anti-interleukin-17A therapies. , 2019, Journal of the American Academy of Dermatology.

[12]  S. Gaffen,et al.  The IL-17 Family of Cytokines in Health and Disease. , 2019, Immunity.

[13]  Mayuko Yamamoto,et al.  Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production. , 2019, Journal of dermatological science.

[14]  M. Lebwohl,et al.  Baseline IL‐22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab , 2019, The Journal of allergy and clinical immunology.

[15]  J. Krueger,et al.  Atopic dermatitis endotypes and implications for targeted therapeutics. , 2019, The Journal of allergy and clinical immunology.

[16]  J. Krueger,et al.  Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis , 2018, The Journal of Immunology.

[17]  H. Young,et al.  Translational repression of pre-formed cytokine-encoding mRNA prevents chronic activation of memory T cells , 2018, Nature Immunology.

[18]  Xiaoju Tang,et al.  Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. , 2018, Journal of dermatological science.

[19]  M. Ståhle,et al.  Dynamic Changes in Resident and Infiltrating Epidermal Dendritic Cells in Active and Resolved Psoriasis. , 2017, The Journal of investigative dermatology.

[20]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[21]  M. Suárez-Fariñas,et al.  Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis , 2017, Experimental dermatology.

[22]  Fabian J Theis,et al.  A novel molecular disease classifier for psoriasis and eczema , 2016, Experimental dermatology.

[23]  R. Nazarian,et al.  Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. , 2015, JAMA dermatology.

[24]  E. Guttman‐Yassky,et al.  Successful use of ustekinumab therapy in refractory severe atopic dermatitis , 2014, JAAD case reports.

[25]  Fabian J Theis,et al.  Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema , 2014, Science Translational Medicine.

[26]  Y. Tada,et al.  IL-22, but Not IL-17, Dominant Environment in Cutaneous T-cell Lymphoma , 2011, Clinical Cancer Research.

[27]  Sandra J Shefelbine,et al.  BoneJ: Free and extensible bone image analysis in ImageJ. , 2010, Bone.

[28]  C. Johansen,et al.  Preferential inhibition of the mRNA expression of p38 mitogen‐activated protein kinase regulated cytokines in psoriatic skin by anti‐TNFα therapy , 2010, The British journal of dermatology.

[29]  Juan Cheng,et al.  Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. , 2010, Clinical immunology.

[30]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[31]  M. Terranova,et al.  The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study , 2007, The British journal of dermatology.

[32]  B. Mougin,et al.  Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. , 2004, Journal of biotechnology.

[33]  W. Pichler,et al.  Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. , 2000, The Journal of allergy and clinical immunology.

[34]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.